Doctor profile · Federal record
Dr. Philip Loria, MD
Dermatology Physician (CMS: Dermatology) · Oxford, MS
- NPI 1760586002
- Accepts Medicare
- MIPS 76.7 / 100 · 2023
- 44 yrs in practice
- Male
- Solo practice
- No sanctions
Practice & contact
- Primary practice
-
2204 Jefferson Davis Drive
Oxford, MS 38655
(662) 236-6850
fax (662) 236-5010
Credentials & registration
- NPI registered
- September 2006 — 20 yrs on file
- Profile last updated
- June 5, 2008
- Year of graduation
- 1982 — 44 yrs since
- Specialty taxonomy
- 207N00000X — NUCC code
- State license (1)
- Mississippi #12732
- Medicaid
- MS #00016031
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1760586002. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
19,577
Distinct HCPCS
10
Medicare allowed
$586,367
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 8,548 | 1,264 | $6 | |
J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 3,992 | 327 | $1 | |
17000 |
Destruction of precancer skin growth, 1 growth | 2,351 | 1,539 | $50 | |
17110 |
Destruction of skin growth, 1-14 growths | 1,222 | 994 | $99 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 650 | 455 | $82 | |
11102 |
Biopsy of related skin growth, first growth | 576 | 494 | $81 | |
99212 |
Established patient office or other outpatient visit, 10-19 minutes | 477 | 436 | $51 | |
96372 |
Injection of drug or substance under skin or into muscle | 405 | 192 | $13 | |
17004 |
Destruction of precancer skin growth, 15 or more growths | 232 | 160 | $150 | |
11103 |
Biopsy of related skin growth, each additional growth | 135 | 94 | $45 |
In context: peer comparison
Among 1 peers in this city , average services per provider: 652. This provider delivers 30× the peer median.Open Payments
Industry payments received
All-time total
$1,222
Transactions
67
Manufacturers
14
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES INC. | 9 | $261.29 | |
| ABBVIE INC. | 19 | $230.13 | |
| Mallinckrodt Hospital Products Inc. | 11 | $228.72 | |
| Amgen Inc. | 12 | $163.59 | |
| UCB, Inc. | 6 | $136.03 | |
| Lilly USA, LLC | 2 | $39.46 | |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $26.19 | |
| Regeneron Healthcare Solutions, Inc. | 1 | $25.84 | |
| Janssen Biotech, Inc. | 1 | $24.37 | |
| Tempus AI, Inc | 1 | $20.57 | |
| Kyowa Kirin, Inc. | 1 | $20.02 | |
| LEO Pharma Inc. | 1 | $19.09 | |
| Galderma Laboratories, L.P. | 1 | $15.35 | |
| Biofrontera Inc. | 1 | $11.07 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
987
Patients
382
Total drug cost
$652,060
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Doxycycline Hyclate | Generic | 216 | 80 | $9,534 |
| Triamcinolone Acetonide | Generic | 201 | 102 | $4,017 |
| Hydroxychloroquine Sulfate | Generic | 90 | 30 | $2,311 |
| Clobetasol Propionate | Generic | 61 | 33 | $4,684 |
| Gabapentin | Generic | 60 | 24 | $1,140 |
| Imiquimod | Generic | 60 | 32 | $2,785 |
| Mometasone Furoate | Generic | 56 | 39 | $1,787 |
| Humira(Cf) Pen (Adalimumab) | Brand | 47 | 0 | $539,102 |
| Mycophenolate Mofetil | Generic | 40 | 0 | $2,667 |
| Terbinafine Hcl | Generic | 36 | 18 | $446 |
Frequently asked questions
What is Dr. Philip Loria's medical specialty?
Dr. Philip Loria practices Dermatology Physician in Oxford, MS.
Where does Dr. Philip Loria practice?
Dr. Philip Loria practices at 2204 Jefferson Davis Drive, Oxford, MS 38655. Office phone: 6622366850.
What is Dr. Philip Loria's NPI?
Dr. Philip Loria's National Provider Identifier (NPI) is 1760586002, issued by NPPES.
Does Dr. Philip Loria accept Medicare assignment?
Yes. Dr. Philip Loria accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Philip Loria commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Injection, triamcinolone acetonide, not otherwise specified, 10 mg (HCPCS J3301); Destruction of precancer skin growth, 1 growth (HCPCS 17000). Source: CMS Medicare Physician & Other Practitioners file.